AstraZeneca Sets $35 Monthly Cap on Inhaler Costs
Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines.
Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines.
The FDA approved osimertinib (Tagrisso) with platinum-based chemotherapy for certain patients with non-small cell lung cancer (NSCLC).
Cedars-Sinai investigators suggest it may be helpful to keep an eye on patients with underlying health issues after COVID-19 vaccination to monitor for post-vaccine POTS, a condition that causes an abnormal increase in heart rate after standing or sitting up.
AstraZeneca's Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
WHO advises retaining the current COVID-19 vaccine antigen composition, one that uses a monovalent XBB.1.5 as the COVID-19 vaccine antigen.